{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:05:19Z","timestamp":1775570719952,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"DOI":"10.7759\/cureus.102935","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:50:32Z","timestamp":1770191432000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Posterior Reversible Encephalopathy Syndrome With Single-Agent Weekly Paclitaxel"],"prefix":"10.7759","author":[{"given":"Mayal","family":"Arshad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Umer","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sohaib","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ali","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateen","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Paclitaxel","author":"Awosika AO","year":"2024","unstructured":"Awosika AO, Farrar MC, Jacobs TF. Paclitaxel. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(84)90025-1","article-title":"Taxol: an antimitotic agent with a new mechanism of action","volume":"25","author":"Manfredi JJ","year":"1984","unstructured":"Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 1984, 25:83-125. 10.1016\/0163-7258(84)90025-1","journal-title":"Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1000","article-title":"Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer","volume":"28","author":"Loesch D","year":"2010","unstructured":"Loesch D, Greco FA, Senzer NN, et al.. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010, 28:2958-65. 10.1200\/JCO.2009.24.1000","journal-title":"J Clin Oncol"},{"key":"ref4","unstructured":"Breast cancer - paclitaxel (7 day). (2019). Accessed. July 24, 2025: https:\/\/www.uhs.nhs.uk\/Media\/UHS-website-2019\/Docs\/Chemotherapy-SOPs1\/Breastcancer\/Paclitaxel-7-day.pdf."},{"key":"ref5","unstructured":"Paclitaxel. (2025). Accessed. July 24, 2025: https:\/\/www.macmillan.org.uk\/cancer-information-and-support\/treatments-and-drugs\/paclitaxel."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey J","year":"1996","unstructured":"Hinchey J, Chaves C, Appignani B, et al.. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996, 334:494-500. 10.1056\/NEJM199602223340803","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.014","article-title":"Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review","volume":"6","author":"Apuri S","year":"2014","unstructured":"Apuri S, Carlin K, Bass E, Nguyen PT, Greene JN. Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review. Mediterr J Hematol Infect Dis. 2014, 6:e2014014. 10.4084\/MJHID.2014.014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari A","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al.. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021, 32:1475-95. 10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-017-0750-6","article-title":"Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome","volume":"117","author":"Faille LD","year":"2017","unstructured":"Faille LD, Fieuws S, Van Paesschen W. Clinical predictors and differential diagnosis of posterior reversible encephalopathy syndrome. Acta Neurol Belg. 2017, 117:469-75. 10.1007\/s13760-017-0750-6","journal-title":"Acta Neurol Belg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207604","article-title":"Demographic disparities in the incidence, clinical characteristics, and outcome of posterior reversible encephalopathy syndrome in the United States","volume":"101(15)","author":"Otite FO","year":"2023","unstructured":"Otite FO, Patel SD, Anikpezie N, et al.. Demographic disparities in the incidence, clinical characteristics, and outcome of posterior reversible encephalopathy syndrome in the United States. Neurology. 2023, 101(15):e1554-9. 10.1212\/WNL.0000000000207604","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2012.00152","article-title":"Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness","volume":"32","author":"Hobson EV","year":"2012","unstructured":"Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 2012, 32:590-4. 10.3747\/pdi.2012.00152","journal-title":"Perit Dial Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo A","year":"2008","unstructured":"Di Leo A, Gomez HL, Aziz Z, et al.. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008, 26:5544-52. 10.1200\/JCO.2008.16.2578","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5152\/balkanmedj.2015.15487","article-title":"Reversible posterior leukoencephalopathy syndrome due to carboplatin and paclitaxel therapy","volume":"32","author":"Kandemir M","year":"2015","unstructured":"Kandemir M, K\u00fc\u00e7\u00fckkaya B, Tepe MS, et al.. Reversible posterior leukoencephalopathy syndrome due to carboplatin and paclitaxel therapy. Balkan Med J. 2015, 32:421-5. 10.5152\/balkanmedj.2015.15487","journal-title":"Balkan Med J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2024.02.073","article-title":"Paclitaxel combined with trastuzumab chemotherapy-related posterior reversible encephalopathy syndrome: a case report and literature review","volume":"19","author":"Li J","year":"2024","unstructured":"Li J, Huang Y, Lao Q. Paclitaxel combined with trastuzumab chemotherapy-related posterior reversible encephalopathy syndrome: a case report and literature review. Radiol Case Rep. 2024, 19:2188-91. 10.1016\/j.radcr.2024.02.073","journal-title":"Radiol Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100548","article-title":"Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer","volume":"31","author":"Foulser PF","year":"2022","unstructured":"Foulser PF, Senthivel N, Downey K, Hart PE, McGrath SE. Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer. Cancer Treat Res Commun. 2022, 31:100548. 10.1016\/j.ctarc.2022.100548","journal-title":"Cancer Treat Res Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/459692-a-case-of-posterior-reversible-encephalopathy-syndrome-with-single-agent-weekly-paclitaxel","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:50:33Z","timestamp":1770191433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/459692-a-case-of-posterior-reversible-encephalopathy-syndrome-with-single-agent-weekly-paclitaxel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.102935","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}